LPCN

Lipocine Inc. develops oral therapies using its proprietary drug delivery technology. The company focuses on treating serious conditions with significant unmet medical needs, including postpartum depression, major depressive disorder, epilepsy, essential tremor, liver cirrhosis, obesity management, and prevention of recurrent pre-term birth. Its product pipeline includes LPCN 1154 for postpartum depression and TLANDO®, an oral testosterone replacement therapy. Lipocine operates primarily in the pharmaceutical sector.